Cogstate (ASX:CGS) 5-Year Yield-on-Cost %: 0.74 (As of Jul. 04, 2026)


ASX:CGS Cogstate Ltd ASX:CGS
77 GF Score
Price A$2.74
GF Value A$2.09
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cogstate 5-Year Yield-on-Cost %?

Cogstate ASX:CGS +1.11% 77 5-Year Yield-on-Cost % is 0.74 as of Jul. 04, 2026. GuruFocus rates ASX:CGS with a GF Score™ of 77/100 and a GF Value™ of A$2.09 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 282 Healthcare Providers & Services companies, Cogstate ranks worse than 84.75% on this metric.

Cogstate's yield on cost for the quarter that ended in Dec. 2025 was 0.74.


The historical rank and industry rank for Cogstate's 5-Year Yield-on-Cost % or its related term are showing as below:

ASX:CGS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.74
Current: 0.74


During the past 13 years, Cogstate's highest Yield on Cost was 0.74. The lowest was 0.00. And the median was 0.00.


ASX:CGS's 5-Year Yield-on-Cost % is ranked worse than
84.75% of 282 companies
in the Healthcare Providers & Services industry
Industry Median: 2.87 vs ASX:CGS: 0.74

Cogstate  (ASX:CGS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cogstate 5-Year Yield-on-Cost % Related Terms


ASX:CGS vs VEEV, BTSG, TEM: 5-Year Yield-on-Cost % Comparison

For the Health Information Services subindustry, Cogstate's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogstate 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cogstate's 5-Year Yield-on-Cost % falls into.


ASX:CGS
77GF Score
Cogstate Ltd ASX:CGS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cogstate is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.74 mean?
Cogstate (ASX:CGS) has a 5-Year Yield-on-Cost % of 0.74 as of Jul. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cogstate and its competitors. According to the industry distribution chart, Cogstate ranks #239 out of 282 companies in the Healthcare Providers & Services industry, placing it in the top 84.8%.
Is Cogstate's 5-Year Yield-on-Cost % too high?
Cogstate's current 5-Year Yield-on-Cost % is 0.74. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.87. Cogstate's value of 0.74 is 74.2% below this industry median. Based on the distribution chart, Cogstate ranks #239 out of 282 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cogstate has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #239 out of 282 companies for 5-Year Yield-on-Cost %. This places Cogstate in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.87. Cogstate's value of 0.74 is 74.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.87, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogstate's current 5-Year Yield-on-Cost % of 0.74 is 74.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cogstate and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogstate's current 5-Year Yield-on-Cost % is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.09, compared to a current price of A$2.74 — trading 31.1% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.74 and 74.2% below the Healthcare Providers & Services industry median of 2.87. Cogstate's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current 5-Year Yield-on-Cost % is 0.74 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.74 is trading 31.1% above its estimated GF Value™ of A$2.09. GuruFocus considers Cogstate to be Significantly Overvalued.

Key valuation signals for ASX:CGS:

  • 5-Year Yield-on-Cost %: 0.74
  • GF Value™: A$2.09 vs. price of A$2.74 (31.1% above fair value)
  • GF Score™: 77/100 with 4 warning signs
  • Industry Position: 74.2% below the Healthcare Providers & Services median (#239 of 282)

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score

Get the complete analysis for ASX:CGS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.74
Price
A$2.09
GF Value